This week in Pulmonary

Nov 17, 2026

Latest episode · 10 min
Editor’s pick

Continuous positive airway pressure versus high-flow nasal oxygen in adults with pneumonia-related acute hypoxemic respiratory failure: A systematic review and meta-analysis.

Across seven studies of pneumonia-related hypoxemic respiratory failure, CPAP was associated with about a quarter fewer intubations than high-flow nasal oxygen, but no difference in mortality or length of stay.

Respiratory Medicine · 2026 · PubMed

This week’s highlights

  1. 01Empirical tuberculosis treatment in infants living with HIV hospitalised with severe pneumonia in Africa (EMPIRICAL): a multicentre, randomised, open-label, 2 × 2 factorial, controlled superiority trial.

    In African infants with severe HIV-associated pneumonia, empirical tuberculosis treatment did not reduce twelve-month mortality versus a microbiologically and clinically guided strategy, though many guided-arm infants started treatment anyway.

    Domínguez-Rodríguez S et al. · The Lancet · 2026

    PMID 43020097

  2. 02Continuous positive airway pressure versus high-flow nasal oxygen in adults with pneumonia-related acute hypoxemic respiratory failure: A systematic review and meta-analysis.

    Across seven studies of pneumonia-related hypoxemic respiratory failure, CPAP was associated with about a quarter fewer intubations than high-flow nasal oxygen, but no difference in mortality or length of stay.

    Bokhari SFH et al. · Respiratory Medicine · 2026

    PMID 43034002

  3. 03The Effect of Telemedicine-Based APAP Management on 24-Hour Ambulatory Blood Pressure in Patients with Obstructive Sleep Apnea: A Randomized Clinical Trial.

    In a randomised trial of 344 patients with suspected sleep apnea, telemedicine-based APAP management was noninferior to in-person care for three-month change in 24-hour blood pressure, with similar adherence.

    Yi H et al. · American Journal of Respiratory and Critical Care Medicine · 2026

    PMID 43035945

  4. 04Optimizing Sepsis Time Zero Definitions Through Associations between Antibiotic Timing and Mortality.

    In data from 145 United States hospitals, antibiotic delay beyond one hour was linked to higher mortality only with hypotension or high lactate, and beyond three hours with acute respiratory failure.

    Rhee C et al. · American Journal of Respiratory and Critical Care Medicine · 2026

    PMID 43016314

  5. 05Comparative Effectiveness of GLP-1 Receptor Agonists versus DPP-4 and SGLT2 Inhibitors in Patients with Bronchiectasis and Type 2 Diabetes.

    In a retrospective matched cohort with bronchiectasis and type 2 diabetes, GLP-1 receptor agonists were associated with lower mortality and respiratory failure, but not with fewer bronchiectasis exacerbations.

    Liao KM et al. · Chest · 2026

    PMID 43025805

  6. 06Cardiovascular effects and mortality of short-acting bronchodilators in asthma and COPD.

    In a Belgian nationwide asthma and COPD cohort, short-acting muscarinic antagonist use was associated with more heart failure, arrhythmia and death, and three or more beta-agonist canisters yearly with higher mortality.

    Van Vaerenbergh F et al. · ERJ Open Research · 2026

    PMID 43011614

  7. 07Low-dose CT Screening and Smoking Cessation: Separate and Joint Associations with Mortality among Ever-Smokers Eligible for Lung Cancer Screening.

    In a post-hoc National Lung Screening Trial analysis, recent quitting was associated with larger reductions in lung cancer and all-cause mortality than low-dose CT screening, which did not lower all-cause mortality.

    Wang H et al. · Journal of Thoracic Oncology · 2026

    PMID 43025700

  8. 08Associations between temperatures, extreme temperature events, and onset of acute exacerbations of COPD: a time-stratified case-crossover study in China.

    In a Chinese registry of COPD exacerbations, cold temperatures and especially compound day-and-night cold spells were associated with exacerbation onset, while higher temperatures were not associated with onset.

    Zhang C et al. · Chest · 2026

    PMID 43014669

  9. 09Reframing disease elimination: an update from the Lancet Commission on chronic obstructive pulmonary disease.

    An update of the Lancet Commission on COPD argues for moving from late-stage management to early recognition, biological stratification and lifelong lung health, measuring success by wellbeing as well as survival.

    Stolz D et al. · The Lancet · 2026

    PMID 43008767

  10. 10How I Do It: An Intensivist's guide to RV Failure and Right Ventricular Assist Devices.

    A case-based expert guide sets out a physiology-driven, stepwise approach to acute right ventricular failure in intensive care, including bedside assessment, hemodynamic support and escalation to mechanical circulatory support.

    Sridhar M et al. · Chest · 2026

    PMID 43025806

Read the weekly briefing

This AudioScholar briefing is generated by artificial intelligence from PubMed abstracts for healthcare professionals and is not medical advice.

This week: empirical tuberculosis treatment does not improve survival in infants with HIV pneumonia, CPAP edges out high-flow oxygen for avoiding intubation, and telemedicine holds its own against clinic visits for sleep apnea blood pressure.

Welcome to This Week in Pulmonary. We're covering 10 papers this week: 3 in depth, 4 in brief, 3 quick signals.

In The Lancet, Domínguez-Rodríguez and colleagues report the EMPIRICAL trial [1], a multicentre, open-label, two by two factorial randomised superiority trial in 19 hospitals across Côte d'Ivoire, Malawi, Mozambique, Uganda, Zambia and Zimbabwe. They enrolled infants aged one to twelve months admitted with severe HIV-associated pneumonia and no known tuberculosis, and 558 infants were analysed. The comparison reported here is six months of empirical four-drug tuberculosis treatment added to standard care, against the currently recommended strategy of starting treatment only on microbiological or clinical grounds. Mortality was high in both arms. By twelve months, 48 percent of infants in the empirical tuberculosis groups had died, compared with 43 percent in the guided groups, and the difference was not statistically significant. There was no difference at fifteen days either, and serious adverse events were similar. The key limitation is contamination: just under half of infants in the guided groups eventually started tuberculosis treatment anyway, at a median of four days, which narrowed the contrast between strategies. The authors set this against their finding for empirical valganciclovir in the same trial. As evidence, this large randomised trial does not support routine empirical tuberculosis treatment over the guided approach in this population.

Staying with pneumonia, in adults this time, Respiratory Medicine published a systematic review and meta-analysis by Bokhari and colleagues [2] comparing continuous positive airway pressure, or CPAP, head to head with high-flow nasal oxygen in pneumonia-related acute hypoxemic respiratory failure, including COVID-19 pneumonia. Seven studies with 1,551 patients met inclusion. CPAP was associated with about a quarter lower risk of intubation within 30 days, graded as moderate certainty, and intubation, when it happened, came roughly 22 hours later. Restricted to the four randomised trials, the reduction was smaller but persisted, at roughly a fifth. There was no difference in 30-day, 90-day or in-hospital mortality, or in length of stay. The main limitation is that the signal comes largely from COVID-19 pneumonia. In non-COVID pneumonia the reduction was not statistically significant, although the test for a subgroup difference was also not significant. The pool is small and mixes trials with observational studies. As evidence, this consolidates the head-to-head comparison: the authors conclude that CPAP probably reduces intubation without a survival or length-of-stay advantage, and describe high-flow oxygen as a reasonable, generally better-tolerated alternative.

In the American Journal of Respiratory and Critical Care Medicine, Yi and colleagues report a randomised non-inferiority trial [3] of 344 participants with suspected obstructive sleep apnea, assigned to three months of telemedicine-based auto-adjusting positive airway pressure management or standard in-person care. The primary outcome was the change in 24-hour mean blood pressure on ambulatory monitoring, with a prespecified non-inferiority margin of 1.5 millimetres of mercury. The between-group difference was about half a millimetre lower with telemedicine in the intention-to-treat analysis, and the trial met its non-inferiority margin in both the intention-to-treat and completer analyses. There was no clear difference in device adherence, patient-reported outcomes or metabolic measures. The main limitation is attrition: only 256 of the 344 participants completed follow-up, about three quarters of those randomised, and three months is a short window for a blood pressure endpoint. As evidence, this randomised trial supports telemedicine as an alternative delivery model for positive airway pressure care when blood pressure is the outcome of interest, while longer-term and hard cardiovascular outcomes remain untested.

Now, four in brief.

Also in the American Journal of Respiratory and Critical Care Medicine, Rhee and colleagues [4] analysed electronic health record data from 145 United States hospitals, covering more than 620,000 encounters with organ dysfunction and antibiotics within six hours, to ask which SEP-1 time zero criteria identify patients harmed by antibiotic delay. Antibiotics at one to three hours rather than within the first hour were linked to higher mortality only when time zero was defined by hypotension or a lactate of at least 4 millimoles per litre, by roughly seven to ten percent. Among patients without those features, delays beyond three hours were linked to about eleven percent higher mortality only in acute respiratory failure. This is observational and weighted for confounding, so it informs measure design without proving causation.

In Chest, Liao and colleagues [5] used the TriNetX federated network for a retrospective, propensity-matched cohort of adults with bronchiectasis and type 2 diabetes. Compared with DPP-4 inhibitors, GLP-1 receptor agonist use was associated with less than half the all-cause mortality and about half the risk of acute respiratory failure, with similar associations against SGLT2 inhibitors. There was no statistically significant reduction in bronchiectasis exacerbations, the most disease-specific outcome. Mortality differences this large in a retrospective database study raise the likelihood of residual confounding and healthy-user effects, so the finding is hypothesis-generating and does not establish disease modification.

ERJ Open Research published a Belgian nationwide cohort by Van Vaerenbergh and colleagues [6], covering about 226,000 adults with asthma and 57,000 with COPD on chronic treatment. Compared with no use, short-acting muscarinic antagonist use, alone or combined with a short-acting beta-agonist, was associated with higher risks of heart failure, arrhythmia and death, up to about 1.7-fold. Three or more beta-agonist canisters a year was associated with about ten percent higher heart failure and mortality risk, while one or two canisters carried no increased risk. As an observational study, these associations may partly reflect underlying disease severity rather than a drug effect.

In the Journal of Thoracic Oncology, Wang and colleagues [7] ran a post-hoc analysis of the National Lung Screening Trial in about 31,500 current smokers and recent quitters, followed for a median of twelve years. Low-dose CT was associated with 12 percent lower lung cancer mortality than chest radiography, but no reduction in all-cause mortality. Quitting within two years before enrolment was associated with roughly a third lower lung cancer and all-cause mortality than continued smoking, in either screening arm. Quitting was not randomised and recent quitting is only a proxy for cessation around screening, but the analysis adds to the case for building cessation into screening programmes.

Three quick signals.

In Chest, Zhang and colleagues [8] used a Chinese registry of 5,634 COPD exacerbations in a case-crossover design and found that cold, and not heat, was associated with exacerbation onset, with compound day-and-night cold spells of two days or more linked to roughly four times the odds. Using admission dates instead of symptom onset weakened these associations by more than 80 percent. The design is observational but controls for fixed patient factors.

In The Lancet, Stolz and colleagues [9] update the Lancet Commission on COPD, arguing for a shift from late-stage management toward early recognition, biological stratification and lifelong lung health, with success measured by daily functioning and quality of life as well as lung function and survival. This is an expert review with no new data.

Also in Chest, Sridhar and colleagues [10] offer a How I Do It guide to acute right ventricular failure in the intensive care unit, covering point-of-care ultrasound, invasive hemodynamics, preload, afterload and contractility, airway management, and escalation to mechanical circulatory support. It is a case-based expert review without new outcome data.

Stepping back across this week's papers, the randomised evidence was mostly null or non-inferior, while the largest effects came from retrospective databases and post-hoc analyses, where confounding by severity and healthy-user effects can produce associations that trials later fail to confirm. The one pooled analysis with a positive signal leaned heavily on pandemic-era data, and its benefit on intubation did not extend to survival, so a process outcome and a hard outcome again moved apart.

If you only have time for one paper this week, make it the CPAP versus high-flow nasal oxygen meta-analysis [2]. It gathers the head-to-head evidence on a choice made every day in pneumonia-related respiratory failure, and reopens the question of whether fewer intubations without a survival difference should decide between the two.

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague, in any specialty, who never has time to keep up with the literature. Tell them about AudioScholar: a ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Use it to choose which papers to read in full.

Get Pulmonary every week

By email, Spotify, Apple or any podcast app.

Listen on Apple PodcastsListen on Spotify

Spot something worth flagging?